The Ongoing Evolution of Anti-VEGF Therapy: A Detailed Examination of the Eylea Market analysis and Its Competitive Positioning Against Biosimilars and Next-Generation Treatments
  The Eylea market, centered around the anti-VEGF agent aflibercept, remains a powerhouse in the treatment of major retinal diseases like wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), yet it stands at a critical juncture driven by fierce competitive and regulatory pressures. The therapy’s established efficacy, proven across numerous clinical trials...
0 Kommentare 0 Geteilt 113 Ansichten 0 Bewertungen
Gesponsert